• 한국발생생물학회지:발생과생식
• /
• 제2권2호
• /
• pp.189-196
• /
• 1998

Growth Hormone Releasing Hormone (GHRH)은 척추동물의 시상하부로부터 합성, 분비되어 시상하부-뇌하수체간의 문맥계를 통해 뇌하수체 전엽에 작용하여 Growth Hormone (GH)의 분비를 촉진한다. 시상하부에서 발현되는 일부 Releasing Hormone 들이 여러 시상하부외 조직에서도 검출되고 조직특이적인 기능을 수행한다는 사실이 여러 연구자들에 의해 밝혀졌다. 이러한 사실들을 배경으로 본 연구자는 GHRH가 흰쥐의 뇌하수체 전엽과 뇌하수체로부터 유래된 종양세포주들에서 발현될 가능성을 조사하였다. GHRH 펩타이드와 mRNA의 존재와 구조를 규명하기 위하여 뇌하수체와 배양 세포를 사용하여 GHRH immunocytochemistry, 방사면역측정법, GHRH PCR과 RNase protection assay를 시행하였다. Immunocytochemistry의 결과 gonadotrope (대형)와 somat-olactotrope (중간형)로 추정되는 세포들에서 GHRH 염색이 나타났고, Somatolactotrope성 종양세포인 GH3 cell 추출물에서 immunoreactive GHRH가 방사면역측정법으로 검출되었다. 3'rapid amplification of cDNA end (3'-RACE)를 시행한 결과, 흰쥐 뇌하수체에 GHRH transcript가 존재하고, 그 3'end 부분이 다른 조직내의 GHRH와 동일함을 확인하였다. GHRH RT-PCR에서도 뇌하수체와 종양세포주들인 $\alpha$T3 cell (gonadotrope성)과 GH3 cell에서 예상 산물들이 증폭되었다. RNase protection assay를 시행한 결과 난소절제에 의해 뇌하수체내 GHRH 유전자 발현이 증가됨을 확인하였다. 이상의 결과는 GHRH가 뇌하수체 전엽의 gonadotrope와 somatotrope에서 발현되고, paracrine 또는 autocrine조절물질로 작용하여 GH 분비 외에도 뇌하수체 전엽 세포들의 분화와 분열등에 관여함을 시사한다.

• 수면정신생리
• /
• 제6권2호
• /
• pp.116-125
• /
• 1999

Objectives: The purpose of this study is to investigate the effect of exercise load on sleep structure and stress hormone secretion during sleep. Methods: Five male physical education students were included in this study after giving their written, informed consents in the Research Institute for Sports Science at the University of Hanyang. All subjects have performed for at least 3 years in a regular aerobic exercises such as football, basketball, and running. The subjects were divided into three groups ; NOE(non-exercise), MDE(middle duration exercise), LDE(long duration excercise). MDE group maintained a total of 120 min exercise, and LDE group maintained a total of 300 min exercise by football, basketball or badminton. All subjects were acclimatized to the experimental sleep condition by spending one night under expermental conditions, including the placement of an intravenous catheter. During the subsequent night(24:00-08:00), somnopolygraphic sleep recordings were obtained, and blood for measuring growth hormone, cortisol, testosterone, and $\beta$-endorphin was collected every 120 min throughout the night. Blood samples were obtained from prominent forearm veins of subjects. Then, the samples were immediately placed in ice and centrifuged within 10 min at 3000 rpm at $4^{\circ}C$. Statistical analyses were performed using the SPSS/$PC^+$. Data were analyzed by one-way ANOVA with repeated measures. Results: No significant differences among groups were observed in sleep latency, total sleep time, stage 2 sleep, and slow wave sleep. However, daytime exercise produced significant changes in stage 1 sleep, REM sleep, stage 2 sleep latency, REM sleep latency and sleep efficiency. Stage 1 sleep, stage 2 sleep latency, and REM sleep latency significantly increased in LDE compared to those of NOE and MDE groups. But the amount of REM sleep significantly decreased in LDE. Sleep efficiency of MDE was higher than those of NOE and LDE. The blood concentrations of growth hormone, testosterone, and cortisol during night sleep were significantly lower in LDE than in NOE. $\beta$-endorphin concentrations in blood during night sleep were not different among groups. Conclusion: The daytime exercise load was significantly related to sleep structure and stress hormone secretion during night sleep. Long duration exercise showed a harmful effect on sleep structure and hormone secretion. However, middle duration exercise had a beneficial effect on sleep structure and hormone secretion during sleep.

• 대한생식의학회:학술대회논문집
• /
• 대한불임학회 1996년도 추계 학술대회 및 정기총회
• /
• pp.11-12
• /
• 1996

• 한국동물학회:학술대회논문집
• /
• 한국동물학회 1998년도 한국생물과학협회 학술발표대회
• /
• pp.230.1-230
• /
• 1998

No Abstract, See Full Text

• Clinical and Experimental Pediatrics
• /
• 제57권9호
• /
• pp.379-383
• /
• 2014

Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. GH treatment at a dose of $35-70{\mu}g/kg/day$ should be considered for those with very marked growth retardation, as these patients require rapid catch-up growth. Factors associated with response to GH treatment during the initial 2-3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. Adverse events due to GH treatment are no more common in the SGA population than in other conditions treated with GH. Early surveillance in growth clinics is strongly recommended for children born SGA who have not caught up. Although high dose of up to 0.067 mg/kg/day are relatively safe for short children with growth failure, clinicians need to remain aware of long-term mortality and morbidity after GH treatment.

• Asian-Australasian Journal of Animal Sciences
• /
• 제2권3호
• /
• pp.254-256
• /
• 1989

• Annals of Pediatric Endocrinology and Metabolism
• /
• 제23권4호
• /
• pp.204-209
• /
• 2018

Purpose: Growth hormone transduction defect (GHTD) is characterized by severe short stature, impaired STAT3 (signal transducer and activator of transcription-3) phosphorylation and overexpression of the cytokine inducible SH2 containing protein (CIS) and p21/CIP1/WAF1. To investigate the role of p21/CIP1/WAF1 in the negative regulation of the growth hormone (GH)/GH receptor and Epidermal Growth Factor (EGF)/EGF Receptor pathways in GHTD. Methods: Fibroblast cultures were developed from gingival biopsies of 1 GHTD patient and 1 control. The protein expression and the cellular localization of p21/CIP1/WAF1 was studied by Western immunoblotting and immunofluorescence, respectively: at the basal state and after induction with $200-{\mu}g/L$ human GH (hGH) (GH200), either with or without siRNA CIS (siCIS); at the basal state and after inductions with $200-{\mu}g/L$ hGH (GH200), $1,000-{\mu}g/L$ hGH (GH1000) or 50-ng/mL EGF. Results: After GH200/siCIS, the protein expression and nuclear localization of p21 were reduced in the patient. After successful induction of GH signaling (control, GH200; patient, GH1000), the protein expression and nuclear localization of p21 were reduced. After induction with EGF, p21 translocated to the cytoplasm in the control, whereas in the GHTD patient it remained located in the nucleus. Conclusion: In the GHTD fibroblasts, when CIS is reduced, either after siCIS or after a higher dose of hGH (GH1000), p21's antiproliferative effect (nuclear localization) is also reduced and GH signaling is activated. There also appears to be a positive relationship between the 2 inhibitors of GH signaling, CIS and p21. Finally, in GHTD, p21 seems to participate in the regulation of both the GH and EGF/EGFR pathways, depending upon its cellular location.

• Childhood Kidney Diseases
• /
• 제13권1호
• /
• pp.14-20
• /
• 2009

Growth retardation is a common consequenc of chronic kidney disease (CKD) in childhood. Many recent clinical and experimental data indicate that growth failure in CKD is mainly due to a relative GH insensitivity and functional IGF-I deficiency. Glucocorticoids also glucocorticoids interfere with the integrity of the somatotropic hormone axis at various levels. Over the past 10 years, recombinant growth hormone (rhGH) has been used to help short children with chronic kidney disease. A GH dosage of 0.35 mg/kg/week (28 IU/$m^2$/week) appears efficient and safe. Some clinical trial data show that final height will be within the normal target height range when GH treatment is continued for many years without remarkable adverse events.

• The Korean Journal of Physiology and Pharmacology
• /
• 제12권5호
• /
• pp.217-223
• /
• 2008

To directly test if elevated glucocorticoids are required for fasting-induced regulation of growth hormone (GH)-releasing hormone (GHRH), GHRH receptors (GHRH-R) and ghrelin receptors (GHS-R) expression, male rats were bilaterally adrenalectomized or sham operated. After 7 days, animals were fed ad libitum or fasted for 48 h. Bilateral adrenalectomy increased hypothalamic GHRH to 146% and decreased neuropeptide Y (NPY) mRNA to 54% of SHAM controls. Pituitary GHRH-R and GHS-R mRNA levels were decreased by adrenalectomy to 30% and 80% of shamoperated controls. In shamoperated rats, fasting suppressed hypothalamic GHRH (49%) and stimulated NPY (166%) mRNA levels, while fasting increased pituitary GHRH-R (391%) and GHS-R (218%) mRNA levels. However, in adrenalectomized rats, fasting failed to alter pituitary GHRH-R mRNA levels, while the fasting-induced suppression of GHRH and elevation of NPY and GHS-R mRNA levels remained intact. In fasted adrenalectomized rats, corticosterone replacement increased GHRH-R mRNA levels and intensified the fasting-induced decrease in GHRH, but did not alter NPY or GHS-R response. These data suggest that elevated glucocorticoids mediate the effects of fasting on hypothalamic GHRH and pituitary GHRH-R expression, while glucocorticoids are likely not the major determinant in fasting-induced increases in hypothalamic NPY and pituitary GHS-R expression.

• 생명과학회지
• /
• 제18권7호
• /
• pp.986-991
• /
• 2008

본 연구는 남자초등학교 4학년생 중 태권도 유품자($1{\sim}2$품)로서 태권도칼슘섭취군(8명), 태권도군(8명), 대조군(8명) 총 24명을 대상으로 하였다. 태권도와 칼슘 섭취가 남자초등학생의 체격, 성장호르몬 및 IGF-1에 미치는 영향을 규명하기 위하여 운동 강도 RPE ($7{\sim}15$), 운동빈도 주 5회, 1회 50분의 지속시간으로 12주간 실시하였다. 칼슘은 1일 1회 저녁에 750 mg을 섭취시킨 결과 다음과 같은 결론을 얻었다. 신장은 집단 내 세 그룹 모두 유의하게 증가하였지만 집단 간에서는 대조군에 비해 태권도군과 태권도칼슘섭취군이 유의하게 증가하였다. 성장호르몬은 대조군이 유의하게 감소하였으며 태권도군과 태권도칼슘섭취군은 대조군에 비해 유의하게 증가하였다. IGF-1은 집단 내 태권도군과 태권도칼슘섭취군이 유의하게 증가하였으며 집단 간에서는 대조군에 비해 태권도군과 태권도칼슘섭취군이 유의하게 증가하였다. 이상의 결과를 통해 초등학생에게 태권도프로그램과 칼슘섭취는 신장과 체중, 성장호르몬 및 IGF-1에 긍정적인 영향을 미쳤으며, 향후 적절한 태권도프로그램개발과 운동처방 및 영양섭취에 대한 지속적인 연구가 요구된다.